In a bid to focus on growth and innovation, Israeli generics drugmaker Teva Pharmaceutical Industries (NYSE: TEVA) is to hive off its active pharmaceutical ingredient (API) business.
Known as TAPI, the company is a major player in the small molecule API industry, with approximately 4,300 employees worldwide.
TAPI serves more than 1,000 clients globally, including biotech and pharma firms, with a range of around 350 products.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze